Cell proliferation in prostate cancer patients with lymph node metastasis: A marker for progression

Liang Cheng, Thomas M. Pisansky, Thomas J. Sebo, Bradley C. Leibovich, Dharamdas M. Ramnani, Amy L. Weaver, Beth G. Scherer, Michael L. Blute, Horst Zincke, David G. Bostwick

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

The biological aggressiveness of lymph node-positive prostate cancer is closely linked to cancer volume in nodal metastases. We evaluated MIB-1 (Ki- 67) labeling index and bcl-2 expression in primary cancer and matched nodal metastases from 138 node-positive patients treated with radical prostatectomy and bilateral pelvic lymphadenectomy between 1987 and 1992 at the Mayo Clinic. One hundred twenty-eight patients (93%) received androgen deprivation therapy within 90 days after radical prostatectomy. Mean patient age was 66 years (range, 51-78). The median follow-up was 6.7 years (range, 0.03-11). MIB-1 (Ki-67) labeling index was determined by digital image analysis, and nodal cancer volume was determined by the grid method. Systemic progression, defined as the presence of distant metastasis documented by biopsy or radiographic examination, was used as an outcome end point in the Cox proportional hazard models. MIB-1 labeling index in nodal metastases was predictive of systemic progression-free survival (P = 0.001). The 8-year systemic progression-free survival was 100% for those with MIB-1 labeling index <3.5% compared with 78% for those with MIB-1 labeling index ≥7.8%. MIB-1 labeling index correlated with Gleason score, DNA ploidy, and nodal cancer volume (P < 0.001, 0.04, and <0.001, respectively). After controlling for nodal cancer volume, MIB-1 labeling index remained significant in predicting systemic progression-free survival (P = 0.047). bcl-2 expression in the primary cancer and lymph node metastasis was associated with systemic progression-free survival in univariate analysis (P = 0.027 and 0.048, respectively but was not significant after adjusting for nodal cancer volume (P = 0.52 and 0.17, respectively). Our data indicate that assessment of cell proliferation in nodal metastasis is predictive of clinical outcome in prostate cancer patients with regional lymph node metastasis.

Original languageEnglish
Pages (from-to)2820-2823
Number of pages4
JournalClinical Cancer Research
Volume5
Issue number10
StatePublished - Oct 1999

Fingerprint

Prostatic Neoplasms
Lymph Nodes
Cell Proliferation
Neoplasm Metastasis
Disease-Free Survival
Neoplasms
Prostatectomy
Neoplasm Grading
Ploidies
Lymph Node Excision
Proportional Hazards Models
Androgens
Biopsy
DNA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cheng, L., Pisansky, T. M., Sebo, T. J., Leibovich, B. C., Ramnani, D. M., Weaver, A. L., ... Bostwick, D. G. (1999). Cell proliferation in prostate cancer patients with lymph node metastasis: A marker for progression. Clinical Cancer Research, 5(10), 2820-2823.

Cell proliferation in prostate cancer patients with lymph node metastasis : A marker for progression. / Cheng, Liang; Pisansky, Thomas M.; Sebo, Thomas J.; Leibovich, Bradley C.; Ramnani, Dharamdas M.; Weaver, Amy L.; Scherer, Beth G.; Blute, Michael L.; Zincke, Horst; Bostwick, David G.

In: Clinical Cancer Research, Vol. 5, No. 10, 10.1999, p. 2820-2823.

Research output: Contribution to journalArticle

Cheng, L, Pisansky, TM, Sebo, TJ, Leibovich, BC, Ramnani, DM, Weaver, AL, Scherer, BG, Blute, ML, Zincke, H & Bostwick, DG 1999, 'Cell proliferation in prostate cancer patients with lymph node metastasis: A marker for progression', Clinical Cancer Research, vol. 5, no. 10, pp. 2820-2823.
Cheng L, Pisansky TM, Sebo TJ, Leibovich BC, Ramnani DM, Weaver AL et al. Cell proliferation in prostate cancer patients with lymph node metastasis: A marker for progression. Clinical Cancer Research. 1999 Oct;5(10):2820-2823.
Cheng, Liang ; Pisansky, Thomas M. ; Sebo, Thomas J. ; Leibovich, Bradley C. ; Ramnani, Dharamdas M. ; Weaver, Amy L. ; Scherer, Beth G. ; Blute, Michael L. ; Zincke, Horst ; Bostwick, David G. / Cell proliferation in prostate cancer patients with lymph node metastasis : A marker for progression. In: Clinical Cancer Research. 1999 ; Vol. 5, No. 10. pp. 2820-2823.
@article{7f1ce5c19ac24dce89719d291f9b8a0b,
title = "Cell proliferation in prostate cancer patients with lymph node metastasis: A marker for progression",
abstract = "The biological aggressiveness of lymph node-positive prostate cancer is closely linked to cancer volume in nodal metastases. We evaluated MIB-1 (Ki- 67) labeling index and bcl-2 expression in primary cancer and matched nodal metastases from 138 node-positive patients treated with radical prostatectomy and bilateral pelvic lymphadenectomy between 1987 and 1992 at the Mayo Clinic. One hundred twenty-eight patients (93{\%}) received androgen deprivation therapy within 90 days after radical prostatectomy. Mean patient age was 66 years (range, 51-78). The median follow-up was 6.7 years (range, 0.03-11). MIB-1 (Ki-67) labeling index was determined by digital image analysis, and nodal cancer volume was determined by the grid method. Systemic progression, defined as the presence of distant metastasis documented by biopsy or radiographic examination, was used as an outcome end point in the Cox proportional hazard models. MIB-1 labeling index in nodal metastases was predictive of systemic progression-free survival (P = 0.001). The 8-year systemic progression-free survival was 100{\%} for those with MIB-1 labeling index <3.5{\%} compared with 78{\%} for those with MIB-1 labeling index ≥7.8{\%}. MIB-1 labeling index correlated with Gleason score, DNA ploidy, and nodal cancer volume (P < 0.001, 0.04, and <0.001, respectively). After controlling for nodal cancer volume, MIB-1 labeling index remained significant in predicting systemic progression-free survival (P = 0.047). bcl-2 expression in the primary cancer and lymph node metastasis was associated with systemic progression-free survival in univariate analysis (P = 0.027 and 0.048, respectively but was not significant after adjusting for nodal cancer volume (P = 0.52 and 0.17, respectively). Our data indicate that assessment of cell proliferation in nodal metastasis is predictive of clinical outcome in prostate cancer patients with regional lymph node metastasis.",
author = "Liang Cheng and Pisansky, {Thomas M.} and Sebo, {Thomas J.} and Leibovich, {Bradley C.} and Ramnani, {Dharamdas M.} and Weaver, {Amy L.} and Scherer, {Beth G.} and Blute, {Michael L.} and Horst Zincke and Bostwick, {David G.}",
year = "1999",
month = "10",
language = "English",
volume = "5",
pages = "2820--2823",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Cell proliferation in prostate cancer patients with lymph node metastasis

T2 - A marker for progression

AU - Cheng, Liang

AU - Pisansky, Thomas M.

AU - Sebo, Thomas J.

AU - Leibovich, Bradley C.

AU - Ramnani, Dharamdas M.

AU - Weaver, Amy L.

AU - Scherer, Beth G.

AU - Blute, Michael L.

AU - Zincke, Horst

AU - Bostwick, David G.

PY - 1999/10

Y1 - 1999/10

N2 - The biological aggressiveness of lymph node-positive prostate cancer is closely linked to cancer volume in nodal metastases. We evaluated MIB-1 (Ki- 67) labeling index and bcl-2 expression in primary cancer and matched nodal metastases from 138 node-positive patients treated with radical prostatectomy and bilateral pelvic lymphadenectomy between 1987 and 1992 at the Mayo Clinic. One hundred twenty-eight patients (93%) received androgen deprivation therapy within 90 days after radical prostatectomy. Mean patient age was 66 years (range, 51-78). The median follow-up was 6.7 years (range, 0.03-11). MIB-1 (Ki-67) labeling index was determined by digital image analysis, and nodal cancer volume was determined by the grid method. Systemic progression, defined as the presence of distant metastasis documented by biopsy or radiographic examination, was used as an outcome end point in the Cox proportional hazard models. MIB-1 labeling index in nodal metastases was predictive of systemic progression-free survival (P = 0.001). The 8-year systemic progression-free survival was 100% for those with MIB-1 labeling index <3.5% compared with 78% for those with MIB-1 labeling index ≥7.8%. MIB-1 labeling index correlated with Gleason score, DNA ploidy, and nodal cancer volume (P < 0.001, 0.04, and <0.001, respectively). After controlling for nodal cancer volume, MIB-1 labeling index remained significant in predicting systemic progression-free survival (P = 0.047). bcl-2 expression in the primary cancer and lymph node metastasis was associated with systemic progression-free survival in univariate analysis (P = 0.027 and 0.048, respectively but was not significant after adjusting for nodal cancer volume (P = 0.52 and 0.17, respectively). Our data indicate that assessment of cell proliferation in nodal metastasis is predictive of clinical outcome in prostate cancer patients with regional lymph node metastasis.

AB - The biological aggressiveness of lymph node-positive prostate cancer is closely linked to cancer volume in nodal metastases. We evaluated MIB-1 (Ki- 67) labeling index and bcl-2 expression in primary cancer and matched nodal metastases from 138 node-positive patients treated with radical prostatectomy and bilateral pelvic lymphadenectomy between 1987 and 1992 at the Mayo Clinic. One hundred twenty-eight patients (93%) received androgen deprivation therapy within 90 days after radical prostatectomy. Mean patient age was 66 years (range, 51-78). The median follow-up was 6.7 years (range, 0.03-11). MIB-1 (Ki-67) labeling index was determined by digital image analysis, and nodal cancer volume was determined by the grid method. Systemic progression, defined as the presence of distant metastasis documented by biopsy or radiographic examination, was used as an outcome end point in the Cox proportional hazard models. MIB-1 labeling index in nodal metastases was predictive of systemic progression-free survival (P = 0.001). The 8-year systemic progression-free survival was 100% for those with MIB-1 labeling index <3.5% compared with 78% for those with MIB-1 labeling index ≥7.8%. MIB-1 labeling index correlated with Gleason score, DNA ploidy, and nodal cancer volume (P < 0.001, 0.04, and <0.001, respectively). After controlling for nodal cancer volume, MIB-1 labeling index remained significant in predicting systemic progression-free survival (P = 0.047). bcl-2 expression in the primary cancer and lymph node metastasis was associated with systemic progression-free survival in univariate analysis (P = 0.027 and 0.048, respectively but was not significant after adjusting for nodal cancer volume (P = 0.52 and 0.17, respectively). Our data indicate that assessment of cell proliferation in nodal metastasis is predictive of clinical outcome in prostate cancer patients with regional lymph node metastasis.

UR - http://www.scopus.com/inward/record.url?scp=0032742243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032742243&partnerID=8YFLogxK

M3 - Article

C2 - 10537347

AN - SCOPUS:0032742243

VL - 5

SP - 2820

EP - 2823

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10

ER -